Skip to main content
Home > BC Innovations > Targets & Mechanisms

Chronological Index of : Targets & Mechanisms

 Current Issue
  • Figure: Triggering AD

    AChE revisited Targets & Mechanisms Triggering AD Neuro-Bio Ltd. has identified a peptide derived from AChE that is overexpressed in the brain centers that degenerate first in Alzheimer's disease (AD), and has …

    Published on 6/30/2016
  • Table: BioCentury Product Profile

    AChE revisited Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product A compound that inhibits binding of an AChE-derived peptide to CHRNA7 Concept Prevent …

    Published on 6/30/2016
  • AChE revisited

    Why Neuro-Bio thinks it's time to revisit the role of AChE in AD

    With a new take on an old target, Neuro-Bio believes a developmental form of AChE holds the key to slowing neurodegeneration in Alzheimer's disease.

    Published on 6/30/2016
  • Hide and seek

    A two-part strategy for chasing dormant breast cancer cells out of hiding

    A two-part mechanism discovered at Duke explains how breast cancer cells enter and hide in bone marrow, and suggests GlycoMimetics' next clinical compound could be used to flush them out.

    Published on 6/23/2016
  • Figure: Bad to the bone

    Hide and seek Targets & Mechanisms Bad to the bone A Duke University team has shown how breast cancer cells that have left the primary tumor invade the bone marrow to create dormant micrometastases capable of …

    Published on 6/23/2016
  • Table: BioCentury Product Profile

    Hide and seek Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product GMI-1359, a dual inhibitor of E selectin and CXCR4 Concept Drive dormant micrometastases out of…

    Published on 6/23/2016
  • Vedanta's horizons

    How microbiome company Vedanta is expanding its microbiome platform

    With a $50 million series B round and new technology, Vedanta is expanding its microbiome platform to turn up or down inflammation to fit the indication.

    Published on 6/16/2016
  • Figure: Axis of diabetes

    The Finnish connection Targets & Mechanisms Axis of diabetes An international research group has found that differences between the standards of living in Russia, Estonia and Finland are linked to differences in …

    Published on 6/16/2016
  • Figure: Battle of the bugs

    The Finnish connection Targets & Mechanisms Battle of the bugs In a study in Cell, an international consortium of researchers showed that susceptibility to Type I diabetes was affected by regional differences in …

    Published on 6/16/2016
  • The Finnish connection

    The microbiome link between Finnish children and Type I diabetes

    By comparing microbiomes of Finnish, Russian and Estonian infants, an international consortium has found a molecular link between Type I diabetes and Bacteroides bacteria.

    Published on 6/16/2016
  • Table: BioCentury Product Profile

    Vedanta's horizons Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product Mixture of 20 Clostridium, Bifidobacterium, Ruminococcus and Bacteroides bacterial species …

    Published on 6/16/2016
  • Dissociating ketamine

    An NMDA receptor-independent ketamine metabolite might bypass the drug's side effects

    The discovery of a ketamine metabolite that alleviates depression without causing psychedelic effects could upend a major hypothesis about the drug's action.

    Published on 5/26/2016
  • Figure: Converting ketamine

    Dissociating ketamine Targets & Mechanisms Converting ketamine Collaborators at NIH and the University of Maryland used the structures of the (R) and (S) enantiomers of ketamine and its hydroxynorketamine (HNK) …

    Published on 5/26/2016
  • Figure: Ketamine mimics

    Dissociating ketamine Targets & Mechanisms Ketamine mimics The anesthetic ketamine is an NMDA receptor antagonist known to have antidepressant activity, but it also causes severe psychedelic side effects. In a …

    Published on 5/26/2016
  • Table: BioCentury Product Profile

    Dissociating ketamine Targets & Mechanisms BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product (2R,6R)-hydroxynorketamine Concept A ketamine metabolite that recapitulates the drug's …

    Published on 5/26/2016
  • Figure: NET inflammation in flu

    Another shot at the flu Targets & Mechanisms NET inflammation in flu A new study in Science from Yale University researchers suggests inhibiting caspase-1 and other caspases could help prevent the excessive …

    Published on 5/12/2016
  • Table: Biocentury Product Profile

    Another shot at the flu Targets & Mechanisms Biocentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product Inhibitors of caspase-1, caspase-4 and caspase-5 Concept Blocking caspase-induced …

    Published on 5/12/2016
  • Another shot at the flu

    Targeting caspases may prevent flu-associated death in the elderly

    Human ex vivo studies and genetic analysis of a mouse model of flu in older humans have identified three caspases as new targets for treating flu in the elderly.

    Published on 5/12/2016
  • Figure: Taking down SAMMSON

    Better call Delilah Targets & Mechanisms Taking down SAMMSON In a study published in Nature, researchers from Catholic University Leuven, Flanders Institute for Biotechnology (VIB) and Ghent University showed the …

    Published on 5/5/2016
  • Table: Biocentury Product Profile

    Better call Delilah Targets & Mechanisms Biocentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product Long non-coding RNA (lncRNA) SAMMSON as marker of malignant melanoma Antisense …

    Published on 5/5/2016
  • Better call Delilah

    Cutting SAMMSON strands to weaken melanoma

    SAMMSON, a newly identified lncRNA, is up-regulated in a wide range of melanomas, irrespective of genetic background, and could lead to new antisense therapeutics.

    Published on 5/5/2016
  • Structural SERT-ainty

    SERT crystallography defines two SSRI binding sites

    The crystal structure of the serotonin transporter has revealed a primary ligand-binding site and an allosteric site that offer opportunities for new drug design.

    Published on 4/21/2016
  • Figure: An SSRI in-SERTs twice

    Structural SERT-ainty Targets & Mechanisms An SSRI in-SERTs twice In a study published in Nature, a team from the Vollum Institute at Oregon Health & Science University (OHSU) has finally solved the crystal …

    Published on 4/21/2016
  • Box: Questioning UCP1

    Brown fat heats up Targets & Mechanisms Questioning UCP1 While there is evidence that manipulating targets such as FGF21, USF1 and SLIT2 promote both metabolic benefits and brown fat activity, it is still not clear…

    Published on 3/10/2016
  • Figure: Feel the burn

    Brown fat heats up Targets & Mechanisms Feel the burn Three studies have identified new molecular targets to treat obesity and metabolic diseases by enhancing thermogenesis - a process in which brown or beige …

    Published on 3/10/2016

< Previous   1  2  3  4  5  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993